Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease

被引:204
|
作者
Jantos-Siwy, Justyna [1 ]
Schiffer, Eric [1 ]
Brand, Korbinian [2 ]
Schumann, Gerhard [2 ]
Rossing, Kasper [3 ]
Delles, Christian [4 ]
Mischak, Harald [1 ]
Metzger, Jochen [1 ]
机构
[1] Mosaiques Diagnost & Therapeut AG, D-30625 Hannover, Germany
[2] Hannover Med Sch, Inst Klin Chem, D-30623 Hannover, Germany
[3] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[4] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
关键词
Biomarker quantification; chronic kidney disease; capillary electrophoresis coupled with mass spectrometry; urinary proteome analysis; STEM-CELL TRANSPLANTATION; CAPILLARY-ELECTROPHORESIS; MASS-SPECTROMETRY; DIABETIC-NEPHROPATHY; CREATININE EXCRETION; DISCOVERY; PROTEINURIA; VALIDATION; PREDICT; SAMPLES;
D O I
10.1021/pr800401m
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A limitation of proteomic methods with respect to their clinical applicability is the lack of possibilities to directly deduce the amount of a protein or peptide from a particular mass spectrometry (MS) spectrum. For quantification of chronic kidney disease (CKD)-specific urinary polypeptides in capillary electrophoresis coupled with mass spectrometry (CE-MS), we compared signal intensity calibration methods based on either urinary creatinine or stable isotope labeled synthetic marker analogues (absolute quantification) with those based on ion counting using highly abundant collagen fragments as nonmarker references (relative quantification). Our results indicate that relative quantification of biomarker excretion based on ion counts in reference to endogenous "housekeeping" peptides is sufficient for the determination of urinary polypeptide levels. The calculation of absolute concentrations via exogenous stable isotope-labeled peptide standards is of no additional benefit.
引用
收藏
页码:268 / 281
页数:14
相关论文
共 50 条
  • [41] Urinary cell-free extrachromosomal circular DNAs: A possible biomarker for chronic kidney disease COMMENT
    Demirci, Selami
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (06):
  • [42] Evaluation of kidney disease knowledge and its determinants among patients with chronic kidney disease
    Gulcicek, Sibel
    Atli, Zeynep
    Erol, Ertugrul
    Ikizler, Talat Alp
    Seyahi, Nurhan
    CLINICAL NEPHROLOGY, 2025, 103 (03) : 213 - 224
  • [43] PPARγ and chronic kidney disease
    Fogo, Agnes B.
    PEDIATRIC NEPHROLOGY, 2011, 26 (03) : 347 - 351
  • [44] Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease
    Kistler, Andreas D.
    Mischak, Harald
    Poster, Diane
    Dakna, Mohammed
    Wuethrich, Rudolf P.
    Serra, Andreas L.
    KIDNEY INTERNATIONAL, 2009, 76 (01) : 89 - 96
  • [45] Albuminuria, Proteinuria, and Urinary Albumin to Protein Ratio in Chronic Kidney Disease
    Wu, Men-Tai
    Lam, King-Kwan
    Lee, Wen-Chin
    Hsu, Kao-Tai
    Wu, Chien-Hsing
    Cheng, Ben-Chung
    Ng, Hwee-Yeong
    Chi, Po-Jui
    Lee, Yueh-Ting
    Lee, Chien-Te
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (02) : 82 - 92
  • [46] Urinary Extracellular Vesicles in Chronic Kidney Disease: From Bench to Bedside?
    Delrue, Charlotte
    De Bruyne, Sander
    Speeckaert, Reinhart
    Speeckaert, Marijn M.
    DIAGNOSTICS, 2023, 13 (03)
  • [47] The urinary proteome infers dysregulation of mitochondrial, lysosomal, and protein reabsorption processes in chronic kidney disease of unknown etiology (CKDu)
    Kolli, Ramya T.
    Gunasekara, Sameera Chathuranga
    Foster, Matthew W.
    Adduri, Sitaramaraju
    Strasma, Anna
    Wyatt, Christina
    Konduru, Nagarjun V.
    De Silva, Mangala C. S.
    Jayasundara, Nishad
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2023, 324 (04) : F387 - F403
  • [48] The controversy of klotho as a potential biomarker in chronic kidney disease
    Yu, Li-Xia
    Li, Sha-Sha
    Sha, Min-Yue
    Kong, Jia-Wei
    Ye, Jian-Ming
    Liu, Qi-Feng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker
    van der Weerd, N. C.
    Grooteman, M. P. C.
    Nube, M. J.
    ter Wee, P. M.
    Swinkels, D. W.
    Gaillard, C. A. J. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2015, 73 (03) : 108 - 118
  • [50] Evaluation of Lipoprotein-Associated Phospholipase A2 as a Prognostic Biomarker in Chronic Kidney Disease
    Qu, Hongling
    Zhang, Guangjun
    Pan, Jianyi
    Huang, Yuli
    Lv, Weibiao
    CLINICAL LABORATORY, 2021, 67 (08) : 1841 - 1845